INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2012

Advanced lipoprotein analysis measures have not been shown to improve cardiovascular outcomes beyond standard risk factors and statin-guided LDL reduction.

Practitioners sometimes utilize advanced lipoprotein analysis to predict risk and individualize lifestyle and drug therapy. However, measures such as LDL and HDL particle number and size, apolipoproteins B and A, and lipoprotein(a) have not met biomarker evaluation standards, and it remains undetermined if they incrementally add to traditional risk factor prediction or improve outcomes. Furthermore, medications like niacin and fenofibrate that alter these parameters failed to show additional cardiovascular risk reduction in recent randomized trials of high-risk patients on statins. The authors note that focusing on LDL cholesterol reduction and statin therapy intensification remains supported by a large body of evidence.

Study type
Narrative review
Who was studied
Patients evaluated for cardiovascular prevention
What was measured
Clinical utility of advanced lipoprotein analysis in cardiovascular risk reduction

THE PAPER

What is the role of advanced lipoprotein analysis in practice?

Robinson JG. J Am Coll Cardiol, 2012.

PubMed 23257303 ↗DOI 10.1016/j.jacc.2012.04.067 ↗

Heart & arteries

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.